Yves Fradet
Chercheur universitaire clinicien
Axe Oncologie
HEJ
G4.610
Québec, QC
Canada G1J 1Z4
Full professor
Department of Surgery
Faculty of Medicine
The research conducted by Dr. Fradet and his team covers a variety of aspects ranging from the analysis and modulation of lifestyle habits (e.g., diet, physical activity, etc.) for the prevention and control of cancer, to the analysis of the impact of the microbiota on cancer and its response to treatment. We also focus on the development of new prognostic approaches based on the discovery and evaluation of different biomarkers able to predict the evolution of cancers or their response to chemotherapy treatments, radiotherapy, and/or immunotherapy. Additionally, we work on the characterization of tumor antigens and the development of new immunotherapeutic approaches by methods combining immunology and molecular biology. Finally, we analyze the efficacy of new drugs or therapeutic modalities in clinical trials. The cancers targeted by our research are mainly urological cancers, particularly bladder and prostate cancers.
To carry out this research, it is essential to have access to quality biological samples and clinical data. An important part of our research is the development of biobanks of clinical samples and data to help researchers here and abroad advance knowledge of bladder and prostate cancers and their clinical management. Our group has participated in the establishment of different biobanks such as URO-1 and BIOCaPPE, as well as various tumor registries. The use of these biobanks and tumor registries has enabled local, national, and international collaborations that have led to important scientific advances.
For more information on past and current research, please refer to the Publications and Projects sections.
Team
Valérie Picard
Employée
HEJ
2260, boulevard Henri BourassaL4.120
Québec, QC
Canada G1J 1Z4 +1 418 525-4444, ext. 67855 Valerie.Picard@crchudequebec.ulaval.ca
Hervé Brisson
Employé
HEJ
2260, boulevard Henri BourassaL4.120
Québec, QC
Canada G1J 1Z4 +1 418 525-4444, ext. 16849 +1 418 691-5562 herve.brisson@crchudequebec.ulaval.ca
Audrey Larouche
Employée
HEJ
2250, boulevard Henri BourassaG4.617
Québec, QC
Canada G1J 1Z4 +1 418 525-4444, ext. 67707 audrey.larouche@crchudequebec.ulaval.ca
Mélanie Tremblay-Boily
Employée
HEJ
2250, boulevard Henri BourassaG4.614
Québec, QC
Canada G1J 1Z4 +1 418 525-4444, ext. 67702 melanie.tremblay-boily@crchudequebec.ulaval.ca
Catherine Gérard
Employée
HEJ
2250, boulevard Henri BourassaG4-614
Québec, QC
Canada G1J 1Z4 +1 418 525-4444, ext. 67704 +1 418 691-2958 Catherine.Gerard@crchudequebec.ulaval.ca
Céline Veilleux
Employée
HEJ
1401, 18e rueG4.663
Québec, QC
Canada G1J 1Z4 +1 418 525-4444, ext. 67727 +1 418 691-5562 Celine.Veilleux@crchudequebec.ulaval.ca
Joanie Deroy-Lambert
Employée
HEJ
2250, boulevard Henri BourassaG4.617
Québec, QC
Canada G1J 1Z4 +1 418 525-4444, ext. 67706 Joanie.Deroy-Lambert@crchudequebec.ulaval.ca
Claire Ménard
Employée
HEJ
2250, boulevard Henri BourassaG4.614
Québec, QC
Canada G1J 1Z4 +1 418 525-4444, ext. 67701 +1 418 691-5562 Claire.Menard@crchudequebec.ulaval.ca
Marilyn Savard
Employée
HEJ
2250, boulevard Henri BourassaG4.615
Québec, QC
Canada G1J 1Z4 +1 418 525-4444, ext. 67703 +1 418 691-3154 Marilyn.Savard@crchudequebec.ulaval.ca
Agnes Mani
Employée
HEJ
1401, 18e rueQuébec, QC
Canada G1J 1Z4 +1 418 525-4444, ext. 67694 +1 418 691-3154 agnes.mani.1@ulaval.ca agnes.mani@crchudequebec.ulaval.ca
Carole Plante
Employée
HEJ
2250, boulevard Henri BourassaG4.634
Québec, QC
Canada G1J 1Z4 +1 418 525-4444, ext. 67712 +1 418 691-2958 Carole.Plante@crchudequebec.ulaval.ca
Alain Bergeron
Employé
HDQ
2260, boulevard Henri BourassaL5.123
Québec, QC
Canada G1J 1Z4 +1 418 525-4444, ext. 67929 Alain.Bergeron@crchudequebec.ulaval.ca
Hélène Hovington
Employée
HEJ
Laboratoire d'Uro-Oncologie Expérimentale CHU de Québec-Université Laval, Site HEJ,Pavillon L 2260 boul. Henri-Bourassa
G4.615
Québec, QC
Canada G1J 1Z4 +1 418 525-4444, ext. 67694 +1 418 691-3154 Helene.Hovington@crchudequebec.ulaval.ca
Anne-Marie Maranda Trahan
Employée
HEJ
2250, boulevard Henri BourassaG4.617
Québec, QC
Canada G1J 1Z4 +1 418 525-4444, ext. 67705 Anne-Marie.Maranda@crchudequebec.ulaval.ca
Marjorie Besançon
Employée
HEJ
2250, boulevard Henri BourassaG4.612
Québec, QC
Canada G1J 1Z4 +1 418 525-4444, ext. 67725 +1 418 691-5562 marjorie.besancon.1@ulaval.ca marjorie.besancon@crchudequebec.ulaval.ca
Christine Gagné
Employée
HEJ
2250, boulevard Henri BourassaG4.612
Québec, QC
Canada G1J 1Z4 +1 418 525-4444, ext. 67709 christine.gagne@crchudequebec.ulaval.ca
Julie Michaud
Employé
HEJ
2250, boulevard Henri BourassaG4.634
Québec, QC
Canada G1J 1Z4 +1 418 525-4444, ext. 67713 julie.michaud@crchudequebec.ulaval.ca
Gentiane Rajaobelison
Employée
HEJ
2250, boulevard Henri BourassaG4.632
Québec, QC
Canada G1J 1Z4 +1 418 525-4444, ext. 67695 gentiane.rajaobelison@crchudequebec.ulaval.ca
Publications
View all-
article De Santis M, Palou Redorta J, Nishiyama H, Krawczyński M, Seyitkuliev A, Novikov A, Guerrero-Ramos F, Zukov R, Kato M, Kawahara T, Goeman L, Puente J, Hellmis E, Powles T, Radziszewski P, Gust KM, Vasey P, Bigot P, Fradet Y, Hunting J, Armstrong J, Boulos S, Hois S, Shore ND and
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial
Lancet 406 (10516), 2025.
-
article Laaraj J, Lachance G, Bergeron A, Fradet Y, Robitaille K, Fradet V
New insights into gut microbiota-prostate cancer crosstalk
Trends Mol Med 31 (9), 2025.
-
article Xu X, Zhu H, Hugh-White R, Livingstone J, Eng S, Zeltser N, Wang Y, Pajdzik K, Chen S, Houlahan KE, Luo W, Liu S, Sheng M, Guo WY, Arbet J, Song Y, Wang M, Zeng Y, Wang S, Zhu G, Gao T, Chen W, Ci X, Xu W, Xu K, Orain M, Picard V, Hovington H, Bergeron A, Lacombe L, Têtu B, Fradet Y, Lupien M, Wei GH, Koritzinsky M, Bristow RG, Fleshner NE, Wu X, Shao Y, He C, Berlin A, van der Kwast T, Leong H, Boutros PC, He HH
The landscape of N6-methyladenosine in localized primary prostate cancer
Nat Genet 57 (4), 2025.
Projects
- Targeting sex steroids to improve the response to bladder cancer immunotherapy, from 2021-10-01 to 2026-09-30
- What are my options? A feasibility study of a personalized primary prevention strategy for women and men at high risk of breast and prostate cancer, from 2022-01-15 to 2026-03-31
- Repurposing bicalutamide to improve the response to immune checkpoint inhibition for treatment of advanced urothelial carcinoma, from 2022-08-01 to 2027-07-31
- Investigation multi-omiques des effets des acides gras oméga-3 et de la sélénonèine sur des organoïdes dérivés de patients atteints de cancer de la prostate., from 2024-07-02 to 2026-07-30
- Gut microbiota biomarkers to personalize treatment of bladder cancer, from 2024-12-01 to 2027-04-30
- A novel prebiotic tailored for men combating prostate cancer, from 2025-12-01 to 2028-01-01
- En route towards prebiotic clinical trials for enhancement of immunotherapies in bladder and prostate cancers, from 2020-06-01 to 2024-04-30
- Developement of a prostate cancer vaccine, from 2022-07-20 to 2025-05-01